- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05850689
Undersøgelse af Lumateperone som supplerende terapi i behandlingen af patienter med svær depressiv lidelse
En randomiseret, dobbeltblind, placebo-kontrolleret multicenterundersøgelse for at vurdere effektiviteten og sikkerheden af Lumateperone som supplerende terapi i behandlingen af patienter med svær depressiv lidelse
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The study will be conducted in three periods:
- Screening Period (up to 2 weeks) during which patient eligibility will be assessed.
- Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio.
- Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Study Contact
- Telefonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studiesteder
-
-
-
Cherven Bryag, Bulgarien, 5980
- Rekruttering
- Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
-
Kardzhali, Bulgarien, 6600
- Rekruttering
- Medical Center Lifemed
-
Pleven, Bulgarien, 5800
- Rekruttering
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgarien, 4004
- Rekruttering
- Medical Center Mentalcare OOD
-
Sofia, Bulgarien, 1680
- Rekruttering
- Medical Center Intermedica, OOD
-
Sofia, Bulgarien, 1510
- Rekruttering
- Medical Center Hera EOOD
-
Sofia, Bulgarien, 1202
- Rekruttering
- MHC - Sofia, EOOD
-
Sofia, Bulgarien, 1431
- Afsluttet
- University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
-
Stara Zagora, Bulgarien, 6003
- Afsluttet
- UMHAT Prof. Dr. St. Kirkovich AD
-
Varna, Bulgarien, 9020
- Rekruttering
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
Alabama
-
Huntsville, Alabama, Forenede Stater, 35801
- Rekruttering
- University of Alabama at Birmingham
-
-
California
-
Pico Rivera, California, Forenede Stater, 90660
- Rekruttering
- CNRI-Los Angeles, LLC
-
-
Connecticut
-
Farmington, Connecticut, Forenede Stater, 06030
- Rekruttering
- University of Connecticut Health Center
-
-
Florida
-
Clermont, Florida, Forenede Stater, 34711
- Afsluttet
- Vertex Clinical Research
-
Hialeah, Florida, Forenede Stater, 33012
- Suspenderet
- New Life Medical Research Center, Inc.
-
Miami, Florida, Forenede Stater, 33122
- Rekruttering
- Premier Clinical Research Institute
-
Miami, Florida, Forenede Stater, 33137
- Rekruttering
- Miami Jewish Health System
-
Tampa, Florida, Forenede Stater, 33629
- Rekruttering
- Interventional Psychiatry of Tampa Bay
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Rekruttering
- The Emory Clinic
-
Decatur, Georgia, Forenede Stater, 30030
- Rekruttering
- CenExeli Research LLC
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Afsluttet
- University of Kansas Medical Center Research Institute
-
Overland Park, Kansas, Forenede Stater, 66210
- Rekruttering
- Collective Medical Research
-
-
Massachusetts
-
Methuen, Massachusetts, Forenede Stater, 01844
- Afsluttet
- ActivMed Practices and Research
-
-
Missouri
-
O'Fallon, Missouri, Forenede Stater, 63368
- Rekruttering
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, Forenede Stater, 08755
- Rekruttering
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, Forenede Stater, 11235
- Rekruttering
- SPRI Clinical Trials, LLC
-
New York, New York, Forenede Stater, 10036
- Rekruttering
- Manhattan Behavioral Medicine
-
-
Ohio
-
Avon Lake, Ohio, Forenede Stater, 44012
- Rekruttering
- Quest Therapeutics of Avon Lake
-
Cincinnati, Ohio, Forenede Stater, 45219
- Rekruttering
- University of Cincinnati Medical Center
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University of Pennsylvania - Perelman School of Medicine
-
-
Texas
-
Houston, Texas, Forenede Stater, 77081
- Rekruttering
- DM Clinical Research
-
Mansfield, Texas, Forenede Stater, 76063
- Afsluttet
- Hawkins Psychiatry, PC
-
Richardson, Texas, Forenede Stater, 75080
- Rekruttering
- Pillar Clinical Research, LLC
-
-
Washington
-
Bellevue, Washington, Forenede Stater, 98007
- Rekruttering
- Northwest Clinical Research Center
-
-
-
-
-
Douai, Frankrig, 59500
- Rekruttering
- Cabinet Medical des Drs Prizac-Desbonnet Scottez
-
Nantes, Frankrig, 44093
- Rekruttering
- CHU de Nantes hotel Dieu
-
Nîmes, Frankrig, 30029
- Rekruttering
- Hopital Caremeau
-
Paris, Frankrig, 75012
- Rekruttering
- Groupe Hospitalier Pitie-Salpetriere
-
Poitiers, Frankrig, 86021
- Rekruttering
- CH Henri Laborit
-
-
-
-
-
Ahmedabad, Indien, 380008
- Suspenderet
- Ratandeep Surgical Hospital And Endoscopy Clinic
-
Ahmedabad, Indien, 380009
- Suspenderet
- Sushrusha Navneet Memorial Hospital
-
Ajmer, Indien, 305001
- Suspenderet
- J L N Medical College and Attached Hospitals
-
Bikaner, Indien, 334001
- Rekruttering
- S P Medical College And Associated Group of Hospitals
-
Bārāmati, Indien, 413102
- Rekruttering
- Baramati Hospital
-
Chandigarh, Indien, 160012
- Rekruttering
- Post Graduate Institute of Medical Education And Research PGIMER
-
Guwahati, Indien, 781032
- Afsluttet
- Gauhati Medical College and Hospital
-
Kolhāpur, Indien, 416001
- Rekruttering
- Swastik Hospital
-
Nagpur, Indien, 440001
- Rekruttering
- KIMS-Kingsway Hospitals
-
Palsāna, Indien, 394315
- Rekruttering
- Divyam Hospital
-
Pune, Indien, 411011
- Rekruttering
- Shree Samarth Hospital
-
Rajkot, Indien, 360001
- Afsluttet
- Nagecha Hospital
-
Wardha, Indien, 442004
- Suspenderet
- Acharya vinoba bhave rural hospital
-
-
-
-
-
Kaunas, Litauen, LT-44279
- Afsluttet
- Romuvos Klinika, JSC
-
Ziegzdriai, Litauen, 53136
- Afsluttet
- Kaunas Hospital of Lithuanian University of Health Sciences Psychiatric Clinic Mariu division
-
-
-
-
-
Belgrade, Serbien, 11000
- Rekruttering
- University Clinical Center of Serbia
-
Belgrade, Serbien, 11000
- Rekruttering
- Institute of Mental Health Serbia
-
Belgrade, Serbien, 11000
- Rekruttering
- Clinical Center Dr Dragisa Misovic Dedinje
-
Kovin, Serbien, 26220
- Rekruttering
- Special Hospital for Psychiatric Diseases Kovin
-
Kragujevac, Serbien, 34000
- Rekruttering
- University Clinical Center Kragujevac
-
Kragujevac, Serbien, 34000
- Rekruttering
- University Clinical Center Kragujevac 1
-
Niš, Serbien, 18000
- Rekruttering
- University Clinical Center NIS 1
-
Niš, Serbien, 18000
- Rekruttering
- University Clinical Center NIS
-
Novi Kneževac, Serbien, 23330
- Rekruttering
- Special Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
-
Barcelona, Spanien, 08036
- Rekruttering
- Hosp. Clinic de Barcelona
-
Barcelona, Spanien, 08035
- Rekruttering
- Hosp Univ Vall D Hebron
-
Madrid, Spanien, 28034
- Afsluttet
- Hosp. Univ. Ramon Y Cajal
-
Sabadell, Spanien, 08208
- Rekruttering
- Hosp.Univ.Parc Tauli
-
Zamora, Spanien, 49021
- Rekruttering
- Hosp. Prov. de Zamora
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Male or female patients between the ages of 18 and 65 years, inclusive;
-
Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:
- The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening;
- Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
- Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
- Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
- Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
-
Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:
- citalopram/escitalopram
- fluoxetine
- paroxetine
- sertraline
- duloxetine
- levomilnacipran/milnacipran (if locally approved for MDD)
- venlafaxine/desvenlafaxine
- bupropion
- vilazodone
- vortioxetine
Exclusion Criteria:
-
Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
- Bipolar Disorder;
-
Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
- Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment;
- Eating disorder;
- Substance use disorders (excluding nicotine);
- Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
- Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
-
The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
-
The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
- At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
- At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
- The patient is considered to be in imminent danger to him/herself or others.
-
The patient has a first MDE at age 60 years or older.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Matching capsules administered orally, once daily |
|
Eksperimentel: Lumateperone 42 mg
|
Lumateperone 42 mg capsules administered orally, once daily |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Montgomery-Asberg Depression Rating Scale
Tidsramme: Day 43
|
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms. |
Day 43
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Global Impression Scale-Severity
Tidsramme: Day 43
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). |
Day 43
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Intra-Cellular Therapies, Inc. Clinical Trial, Intra-Cellular Therapies, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ITI-007-505
- ITI-007-505 (Anden identifikator: Janssen Research & Development, LLC)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .